Protara Therapeutics (TARA) slipped ~6% in the premarket on Wednesday after posting interim data from a mid-stage trial for its lead candidate, TARA-002, in children with lymphatic malformations, a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results